Northwest & Ethical Investments L.P. Acquires New Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Northwest & Ethical Investments L.P. purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 13,400 shares of the medical research company's stock, valued at approximately $3,175,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Advisors Asset Management Inc. increased its position in shares of IQVIA by 106.4% in the first quarter. Advisors Asset Management Inc. now owns 1,298 shares of the medical research company's stock worth $328,000 after acquiring an additional 669 shares in the last quarter. B. Riley Wealth Advisors Inc. increased its position in shares of IQVIA by 13.9% in the first quarter. B. Riley Wealth Advisors Inc. now owns 3,568 shares of the medical research company's stock worth $902,000 after acquiring an additional 436 shares in the last quarter. Tidal Investments LLC increased its position in shares of IQVIA by 101.9% in the first quarter. Tidal Investments LLC now owns 7,637 shares of the medical research company's stock worth $1,931,000 after acquiring an additional 3,854 shares in the last quarter. Comerica Bank increased its position in shares of IQVIA by 2.9% in the first quarter. Comerica Bank now owns 41,440 shares of the medical research company's stock worth $10,480,000 after acquiring an additional 1,161 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of IQVIA in the first quarter worth $979,000. Institutional investors and hedge funds own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. StockNews.com lowered shares of IQVIA from a "buy" rating to a "hold" rating in a report on Thursday. Morgan Stanley lowered their price target on shares of IQVIA from $280.00 to $265.00 and set an "overweight" rating for the company in a report on Monday, November 4th. Redburn Atlantic assumed coverage on shares of IQVIA in a report on Monday, October 14th. They set a "buy" rating and a $276.00 price target for the company. Robert W. Baird lowered their price target on shares of IQVIA from $256.00 to $223.00 and set a "neutral" rating for the company in a report on Friday, November 1st. Finally, BTIG Research reduced their price objective on shares of IQVIA from $290.00 to $260.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Five analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, IQVIA currently has an average rating of "Moderate Buy" and a consensus target price of $256.50.

IQVIA Stock Performance

Shares of IQVIA stock traded down $0.47 during trading hours on Friday, reaching $200.96. The company's stock had a trading volume of 513,712 shares, compared to its average volume of 1,174,636. The stock has a market cap of $36.47 billion, a P/E ratio of 26.37, a price-to-earnings-growth ratio of 2.07 and a beta of 1.51. The company's 50 day simple moving average is $218.67 and its 200 day simple moving average is $226.20. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.